Page last updated: 2024-12-05

sulfamonomethoxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfamonomethoxine is a sulfonamide antibiotic that was widely used in the past to treat bacterial infections in humans and animals. It is a synthetic compound, meaning it is not found naturally, and is synthesized through a multi-step chemical process. Sulfamonomethoxine works by inhibiting the production of dihydrofolic acid, a molecule essential for bacterial growth. This action disrupts the bacterial metabolism, leading to bacterial death. However, sulfamonomethoxine is no longer widely used in humans due to its potential side effects, such as allergic reactions, blood disorders, and kidney damage. It is still used in some veterinary applications to treat bacterial infections in animals, particularly in livestock. Sulfamonomethoxine is studied to understand its mechanisms of action, develop new and safer antibiotics, and investigate its potential for other therapeutic applications. Despite its limited human use, sulfamonomethoxine serves as a valuable model for investigating the structure-activity relationships of sulfonamide antibiotics.'

Sulfamonomethoxine: Long acting sulfonamide antibacterial agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5332
CHEMBL ID462990
CHEBI ID32164
SCHEMBL ID93784
MeSH IDM0020752

Synonyms (128)

Synonym
AC-14922
unii-u700p169w2
u700p169w2 ,
5-25-12-00493 (beilstein handbook reference)
nsc 757862
BRD-K14116214-001-04-7
MLS000079369
KBIO1_000949
DIVK1C_000949
SPECTRUM_001414
BPBIO1_000821
IDI1_000949
PRESTWICK_105
NCGC00016572-01
cas-1220-83-3
BSPBIO_000745
OPREA1_147724
1220-83-3
sulfamonomethoxine
PRESTWICK2_000823
AB00052221
4-amino-n-(6-methoxypyrimidin-4-yl)benzenesulfonamide
ro43476
benzenesulfonamide, 4-amino-n-(6-methoxy-4-pyrimidinyl)-
D01141
sulfamonomethoxine (jan/usan/inn)
SPECTRUM5_000985
NCGC00023060-05
NCGC00023060-04
sulfamonomethoxine [usan:inn:ban:jan]
sulfamonomethoxin
ici 32525
sulfamonometoxina [inn-spanish]
n(sup 1)-(6-methoxy-4-pyrimidinyl)sulfanilamide
sulfanilamide, n(sup 1)-(6-methoxy-4-pyrimidinyl)-
daimeton
ds-36
brn 0621128
ro 4-3476
n1-(6-methoxy-4-pyrimidinyl)sulfanilamide
dj-1550
sulfamonomethoxinum [inn-latin]
MLS000069737
smr000036718
KBIOSS_001894
KBIO3_001886
KBIO2_007030
KBIOGR_001503
KBIO2_004462
KBIO2_001894
NINDS_000949
SPBIO_002666
SPBIO_001522
PRESTWICK1_000823
SPECTRUM3_000913
SPECTRUM4_001012
SPECTRUM2_001421
PRESTWICK0_000823
SPECTRUM1501147
PRESTWICK3_000823
NCGC00016572-02
NCGC00016572-03
HMS2092H07
AKOS000308735
STL089636
HMS502P11
4-amino-n-(6-methoxy-4-pyrimidinyl)benzenesulfonamide
n-(6-methoxy-4-pyrimidinyl)sulfanilamide
S0592
HMS1921J21
HMS1570F07
nsc-757862
CHEMBL462990
chebi:32164 ,
A804842
HMS2097F07
4-amino-n-(6-methoxypyrimidin-4-yl)benzene-1-sulfonamide
4-amino-n-(6-methoxy-pyrimidin-4-yl)-benzenesulfonamide
nsc757862
pharmakon1600-01501147
dtxcid6025351
dtxsid8045351 ,
tox21_110502
sulfamonomethoxinum
sulfamonometoxina
S3644
CCG-38995
NCGC00016572-04
NCGC00016572-07
NCGC00016572-06
NCGC00016572-05
NCGC00016572-08
FT-0633498
BBL023014
AB00052221-12
SCHEMBL93784
tox21_110502_1
NCGC00016572-12
sulfamonomethoxine [jan]
sulfamonomethoxine [usan]
sulfamonomethoxine [inn]
sulfamonomethoxine [mart.]
sulfamonomethoxine [who-dd]
CS-4419
HY-B0946
AB00052221_14
mfcd00063466
J-524311
J-004759
sr-01000000177
SR-01000000177-3
sulfamonomethoxine, vetranal(tm), analytical standard
AS-70089
SR-01000000177-4
SBI-0051659.P002
HMS3714F07
4-amino-n-(6-methoxy-4-pyrimidinyl)-benzenesulfonamide
sulfamonmethoxine
gtpl12688
Q27114805
sulfamonomethoxine 100 microg/ml in acetonitrile
BRD-K14116214-001-07-0
1416768-32-5
C71832
k4y ,
sulfamonomethoxine 1000 microg/ml in acetonitrile
4-amino-n-(6-methoxy-pyrimidin-4-yl)-benzene-13c6-sulfonamide hydrate (see data sheet)
1ST4040

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This study investigated the potentially adverse effects of SMM on aquatic organisms and revealed that microalgae exhibited higher sensitivity to SMM than cladocerans did."( Toxicity of the veterinary sulfonamide antibiotic sulfamonomethoxine to five aquatic organisms.
Hou, JH; Huang, DJ; Kuo, TF; Lai, HT, 2014
)
0.66

Pharmacokinetics

ExcerptReferenceRelevance
" SMMNa suspension was used for pharmacokinetic study."( An appropriate ingestion volume of oral sulfa drug suspension in pigs.
Kokue, E; Shimoda, M; Suzuki, R, 1989
)
0.28
" Both the Cmax and tmax of SMM and SMZ ranged widely."( Pharmacokinetics of oral sulfa drugs and gastric emptying in the pig.
Kokue, E; Sakurada, K; Shimoda, M; Wada, J, 1988
)
0.27
"The pharmacokinetic profile of a sulphamonomethoxine-trimethoprim (SMM-TMP) combination was investigated in five horses."( Pharmacokinetic profile of sulphamonomethoxine-trimethoprim in horses after intravenous, intramuscular and oral administration.
Bignazzi, R; Carli, S; Montesissa, C; Sonzogni, O; Villa, R, 1993
)
0.29
"Sulphamonomethoxine (SMM), sulphadimidine (SDD), sulphadiazine (SDZ) and their N4-acetyl derivatives (AcSMM, AcSDD and AcSDZ) were intravenously injected into Goettingen miniature pigs and deacetylation was evaluated from plasma concentration-time curves, renal excretion, and rate constants obtained from pharmacokinetic analysis, using a non-linear least-squares method."( Deacetylation as a determinant of sulphonamide pharmacokinetics in pigs.
Fujii, C; Okamoto, K; Shimoda, M; Sikazwe, G; Son, DS, 1997
)
0.3
"The pharmacokinetic profiles of sulfamonomethoxine (SMM) were investigated in flatfish tongue soles in the present study."( Pharmacokinetics of sulfamonomethoxine in tongue sole (Cynoglossus semilaevis) after intravenous and oral administration.
Chang, ZQ; Li, J; Li, JB; Li, ZX; Wang, YZ, 2014
)
1.01
" Therefore, the present study aimed to investigate pharmacokinetically the usefulness of the oral route in cattle by comparing the oral pharmacokinetic properties of two sulfonamides with different physicochemical properties."( Oral pharmacokinetics of sulfadiazine and sulfamonomethoxine in female Holstein milking cows.
Abugomaa, A; Elbadawy, M; Miura, R; Saiga, M; Sasaki, K; Shimoda, M; Tajima, T; Usui, T; Yamamoto, H, 2023
)
1.17

Compound-Compound Interactions

ExcerptReferenceRelevance
"Experiments on white rats showed that single administration of sulfadimesin or sulfamonomethoxin combined with UV irradiation delays absorption, increases acetylation rate and diminishes excretion of the drugs with urine."( [Sulfadimezine and sulfamomomethoxine distribution in the body of white rats in single and repeated administration in combination with UV irradiation].
Matveeva, SA,
)
0.13
"Chronic treatment with sulfadimesin or sulfamonomethoxin combined with UV irradiation leads to potentiation of adrenocortical function."( [Several indices of the functional state of the adrenals of white rats during a prescribed course of sulfadimezine and sulfamonomethoxine combined with UV-irradiation].
Matveeva, SA,
)
0.34

Bioavailability

ExcerptReferenceRelevance
"The influence of ingested volume of a sulfa drug suspension, sodium sulfamonomethoxine (SMMNa), on the oral pharmacokinetics was studied in pigs, with regard to bioavailability and gastric emptying."( An appropriate ingestion volume of oral sulfa drug suspension in pigs.
Kokue, E; Shimoda, M; Suzuki, R, 1989
)
0.51
" The absorption rate of the free forms of sulfanilamides was increased (significantly for sulfalen and sulfapyridazine)."( [Sulfanilamide absorption and acetylation in rats with experimental hyperlipidemia and cellular regulation of the process of acetylation].
Lubiankina, SV; Makarov, VA; Suetina, IV; Vasilenko, IuK; Vaskanian, VL,
)
0.13
" Bioavailability of the drugs in aqueous solution was good: about 72 per cent and 84 per cent for SMM and about 84 per cent and 98 per cent for TMP following intramuscular and oral administration, respectively."( Pharmacokinetic profile of sulphamonomethoxine-trimethoprim in horses after intravenous, intramuscular and oral administration.
Bignazzi, R; Carli, S; Montesissa, C; Sonzogni, O; Villa, R, 1993
)
0.29
"5 h, and the mean systemic bioavailability (F) was 39."( Pharmacokinetics of sulfamonomethoxine in tongue sole (Cynoglossus semilaevis) after intravenous and oral administration.
Chang, ZQ; Li, J; Li, JB; Li, ZX; Wang, YZ, 2014
)
0.73
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" It is recommended that the initial and maintenance doses be not less than 1000 and 500 mg for both dosage forms respectively."( [Human pharmacokinetic characteristics of sulfamonomethoxine depending on the drug form].
Geĭtman, IIa; Kivman, GIa; Neugodova, NP; Tseĭtlin, NN,
)
0.4
" Brief clinical characteristics of sulfation, its administration routes, doses, dosage advantages and better tolerance as compared to co-trimethoxazole+ (biseptol) are described."( [A new drug sulfaton in the combined treatment of infections with sulfanilamide derivatives and diaminopyrimidine].
Padeĭskaia, EN, 1989
)
0.28
" For each drug, 13-18 groups (n = 5-10 individuals/group) of the dosed animals were killed at different post-dosing times."( Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits.
Guo, WX; Hu, GZ; Li, SF; Li, SY; Li, T; Meng, FD; Qiao, GL; Qiu, YS; Yie, HL; Zhang, XY, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency15.84890.00255.840031.6228AID899
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency1.58490.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1845759Cytoprotective activity against mouse PD-1 stimulated T cell assessed as rescue of PD-1 stimulated inhibition of IFN-gamma production by ELISA2021European journal of medicinal chemistry, Mar-05, Volume: 213Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (112)

TimeframeStudies, This Drug (%)All Drugs %
pre-199032 (28.57)18.7374
1990's17 (15.18)18.2507
2000's14 (12.50)29.6817
2010's32 (28.57)24.3611
2020's17 (15.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.66 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index56.60 (26.88)
Search Engine Supply Index2.91 (0.95)

This Compound (30.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (3.17%)5.53%
Reviews3 (2.38%)6.00%
Case Studies3 (2.38%)4.05%
Observational0 (0.00%)0.25%
Other116 (92.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]